References
  1. Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. .Nat Med. 2021 Apr 1. doi: 10.1038/s41591-021-01325-6
  2. Krammer F., Srivastava K., the PARIS team, Simon V. Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine MedRxiv [Preprint].2021a. doi.org/10.1101/2021.01.29.21250653
  3. Tré-Hardy M, Cupaiolo R, Papleux E, Wilmet A, Horeanga A, Antoine-Moussiaux T, et al. Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers. J Infect. 2021 Mar 31:S0163-4453(21)00158-4. doi: 10.1016/j.jinf.2021.03.025
  4. Prokop M., van Everdingen W., van Rees Vellinga T., Quarles van Ufford, H. Lauran Stöger, Beenen L., Geurts B.  CO-RADS: A Categorical CT Assessment Scheme for Patients Suspected of Having COVID-19-Definition and Evaluation. •Radiology 2020;296: e97-e104. doi.org/10.1148/radiol.2020201473
  5. Wise J. Covid-19: T-cell response lasts for at least six months after infection,.BMJ. 2020;371:m4257. doi: 10.1136/bmj.m4257.
  6. Pradenas E., Trinité B., Urrea V., Marfil S., Ávila-Nieto C., Rodríguez de la Concepción ML. et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. Med (N Y) 2020;2(3):313-320.e4. doi: 10.1016/j.medj.2021.01.005
  7. Jabal KA., Ben-Amram H., Beiruti K., Batheesh Y., Sussan C., Zarka S. et al. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveillance. 2021;26(6):pii=2100096. doi.org/10.2807/1560-7917.ES.2021.26.6.2100096
  8. Krammer F., Srivastava K., Alshammary H., Amoako AA., Awawda MH., Beach KF., et al., Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021b Mar 10. doi: 10.1056/NEJMc2101667
  9. Saadat S., Rikhtegaran-Tehrani Z., Logue J., Newman M., Frieman MB., Harris AD., et al. Single dose vaccination in healthcare workers previously infected with SARS-CoV-2. MedRxiv [Preprint].2021. doi.org/10.1101/2021.01.30.21250843
  10. Arvin AM., Fink K., Schmid MA., Cathcart A., Spreafico R., Havenar-Daughton C.,et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020;584(7821):353-363. doi: 10.1038/s41586-020-2538-8.
  11. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines- a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-279. doi: 10.1038/nrd.2017.243
  12. Alber AB., Suter DM. Dynamics of protein synthesis and degradation through the cell cycle. Cell Cycle. 2019; 18(8): 784–794. doi: 10.1080/15384101.2019.1598725
  13. Volkov IL., Johansson M. Single-Molecule Tracking Approaches to Protein Synthesis Kinetics in Living Cells. Biochemistry. 2019, 58, 1, 7–14. doi.org/10.1021/acs.biochem.8b00917
  14. Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, et al. Trained immunity: A program of innate immune memory in health and disease. Science. 2016;352(6284):aaf1098. doi: 10.1126/science.aaf1098.